About Genovis AB 
Genovis AB
Pharmaceuticals & Biotechnology
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Company Coordinates 
Company Details
Medicon Village, Scheelevagen 2 , LUND None : 223 63
Registrar Details
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Management
Designation
Ms. Sarah Fredriksson
Chairman of the Board
Mr. Peter Hein
Director
Ms. Lotta Ljungqvist
Director
Mr. Mikael Lonn
Director
Mr. Kenth Petersson
Director
Ms. Lena Soderstrom
Director
Revenue and Profits:
Net Sales:
29 Million
(Quarterly Results - Jun 2025)
Net Profit:
5 Million
Pharmaceuticals & Biotechnology
SEK 1,391 Million (Small Cap)
52.00
NA
0.00%
-0.58
8.04%
5.28






